BioMarin faces make-or-break FDA panel vote; Ackman re-ups his Valeant stake;

@FierceBiotech: Genmab's lymphoma project flops in Phase III with Novartis holding the bag. Article | Follow @FierceBiotech

@JohnCFierce: Any journos who would like to attend our  breakfast event on Big Data? Drop me a line @ [email protected] More info | Follow @JohnCFierce

@DamianFierce: Has anyone asked the presumptive FDA chief whether jet fuel can melt steel? More | Follow @DamianFierce

> BioMarin ($BMRN) is in the midst of a make-or-break meeting with FDA advisers over its in-development treatment for Duchenne muscular dystrophy. The Street's Adam Feuerstein is live-blogging the daylong discussion. More

> Bill Ackman, long a vocal supporter of the embattled Valeant Pharmaceuticals ($VRX), has acquired an even greater stake in the company. More

> Array BioPharma's ($ARRY) chief financial officer is stepping down after four months on the job. News

Medical Device News

@FierceMedDev: Startup gets $36.5M to conduct U.S. pivotal trial for novel endoscopic weight loss device. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Physicians call for novel abuse-deterrent opioid agonist/antagonist formulations in survey. FierceDrugDelivery story | Follow @VarunSaxena2

@EmilyWFierce: Dell teams up with Zebra Medical Vision for data analytics initiative. Report | Follow @EmilyWFierce

> Dell teams up with Zebra Medical Vision for data analytics initiative. Story

> Cigna launches genetic counseling program for hereditary cancers. Article

Pharma News

@FiercePharma: Japan's Takeda gets early U.S. FDA nod for ixazomib. More from FiercePharmaAsia | Follow @FiercePharma

@EricPFierce: ICYMI: Catalent halts production, calls authorities into French plant where tampering is suspected. Article | Follow @EricPFierce

@CarlyHFierce: With veteran job-choppers Pfizer and Allergan joining hands, how many layoffs are in the cards? More | Follow @CarlyHFierce

> Trump, Clinton lash out at Pfizer over Allergan deal agreement. More

> Forget Pfizer and Allergan, Teva is the pharma getting the most market love these days. Report

> JAMA: Gilead, AbbVie hep C meds cost-effective even in early stages of liver disease. Article

Drug Delivery News

> Depomed acquires pain candidate for $25M as it fends off Horizon's hostile takeover. Item

> AstraZeneca begins dosing in trial of its Bind-partnered cancer candidate. More

> J&J leads $24M financing into maker of OTC 'liquid shots' for common ailments. Report

> Pills loaded with mucoadhesive patches could make oral insulin a reality. Story

> Adapt Pharma earns FDA approval of first intranasal spray for emergency opioid overdose. Article

Pharma Manufacturing News

> Novo Nordisk says all its manufacturing plants will run on renewable electricity by 2020. News

> Abzena to raise $30M to buy another U.S. contract drug developer. Report

> Some production resumes at Strides Shasun facility following fire that killed one. More

> Synerlab buys contract manufacturing developer Alcala Farma for undisclosed price. Story

> South Africa's Ascendis picks up manufacturing facility in $24.6M deal for Akacia. Article

Pharma Asia News

> India's Biocon chief says R&D tax breaks essential for investment. Story

> China's ZAI Lab in oncology license deal for HM61713 with South Korea's Hanmi. More

> India's gliptin market ready for a shakeup by Zydus at 11 U.S. cents a pill. Report

> Japan's Takeda gets early U.S. FDA nod for ixazomib. Item

> India-EU trade talks back on next year, GVK issue sidelined. Article

Suggested Articles

Biogen unveiled full phase 1/2 for a prospect that emerged from a shift in its thinking about treating amyotrophic lateral sclerosis.

It took a little longer than expected, but Biogen’s done it—along with partner Eisai, the Big Biotech has completed an FDA filing for aducanumab.

Gilead is ditching a new avenue of treating hepatitis B as it cuts ties with Precision Biosciences less than two years into their research pact.